IM ketorolac vs diclofenac potassium powder for oral solution for the acute treatment of severe migraine: a randomized c
- PDF / 289,426 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 101 Downloads / 171 Views
REVIEW ARTICLE
IM ketorolac vs diclofenac potassium powder for oral solution for the acute treatment of severe migraine: a randomized controlled trial Emily Rubenstein Engel 1
&
Joshua Cheng 2
Received: 30 July 2019 / Accepted: 14 November 2019 # Fondazione Società Italiana di Neurologia 2019
Abstract Background Diclofenac potassium for oral solution (CAMBIA®) may be an alternative for patients who would otherwise need to be seen in a healthcare setting for parenteral ketorolac. CAMBIA® is FDA-approved for the abortive treatment of migraine and has demonstrated superiority over generic diclofenac tablets with rapid migraine reduction. This study assessed for efficacy of CAMBIA® as an alternative outpatient treatment for refractory migraine to parenteral ketorolac. Methods We performed an exploratory, single-center, double-blind, double-dummy randomized controlled trial comparing CAMBIA® with IM ketorolac. Participants were randomized to receive either ketorolac 60 mg IM with dummy oral solution or CAMBIA® 50 mg, together with IM injection of normal saline. The primary endpoint was headache severity, self-rated on a scale 0–3. Secondary endpoints included self-rated nausea, disability, and photo- or phonophobia, as well as presence of side effects and need for additional rescue therapy. Results A total of 23 patients were enrolled. Ten patients received the study drug and 13 patients received IM ketorolac as the control. There were no major differences observed with respect to the primary outcome of mean headache severity at successive time points over a 24-h follow-up period. No major differences were found with respect to average disability, nausea, and photoor phonophobia ratings. No major adverse events were reported. Conclusion In treatment of refractory migraine headache, CAMBIA® may provide similar benefits as IM ketorolac without increasing the risk of treatment failure, major bleeding, or cardiovascular events. However, larger studies are needed to confirm this finding. Trial registration Clinicaltrials.gov: NCT # 02664116, Titled “IM Ketorolac vs Diclofenac Potassium Powder for Oral Solution (CAMBIA®) for the Acute Treatment of Severe Migraine”. Registered 26 January 2016, https://clinicaltrials.gov/ct2/show/ NCT02664116?term=02664116&rank=1 Keywords Diclofenac . Ketorolac . CAMBIA® . Migraine . Headache
Background * Emily Rubenstein Engel [email protected] Joshua Cheng [email protected] 1
Dalessio Headache Center Scripps Clinic Division of Neurology, 10666 North Torrey Pines Rd. MS 313, La Jolla, CA 92037, USA
2
Scripps Green Hospital, SCMG Hospitalists, 10666 N. Torrey Pines Rd, La Jolla, CA 92037, USA
Migraine is an impairing neurologic condition that affects an estimated 10% of the global population [1] with a reported prevalence affecting approximately 15% of Americans annually which equates to approximately 1 out of every 7 adults [2]. A migraine will classically present as attacks of throbbing and unilateral headaches, often associated with nausea, vomiting, photoph
Data Loading...
